dc.contributor.author |
Dziwornu, Godwin Akpeko
|
|
dc.contributor.author |
Coertzen, Dina
|
|
dc.contributor.author |
Leshabane, Meta Kgaogelo
|
|
dc.contributor.author |
Korkor, Constance M.
|
|
dc.contributor.author |
Cloete, Cleavon K.
|
|
dc.contributor.author |
Njoroge, Mathew
|
|
dc.contributor.author |
Gibhard, Liezl
|
|
dc.contributor.author |
Lawrence, Nina
|
|
dc.contributor.author |
Reader, Janette
|
|
dc.contributor.author |
Van der Watt, Mariette Elizabeth
|
|
dc.contributor.author |
Wittlin, Sergio
|
|
dc.contributor.author |
Birkholtz, Lyn-Marie
|
|
dc.contributor.author |
Chibale, Kelly
|
|
dc.date.accessioned |
2021-07-21T13:40:25Z |
|
dc.date.issued |
2021-04 |
|
dc.description.abstract |
A novel series of antimalarial benzimidazole derivatives incorporating phenolic Mannich base side chains at the C2 position, which possess dual asexual blood and sexual stage activities, is presented. Structure–activity relationship studies revealed that the 1-benzylbenzimidazole analogues possessed submicromolar asexual blood and sexual stage activities in contrast to the 1H-benzimidazole analogues, which were only active against asexual blood stage (ABS) parasites. Further, the former demonstrated microtubule inhibitory activity in ABS parasites but more significantly in stage II/III gametocytes. In addition to being bona fide inhibitors of hemozoin formation, the 1H-benzimidazole analogues also showed inhibitory effects on microtubules. In vivo efficacy studies in Plasmodium berghei-infected mice revealed that the frontrunner compound 41 exhibited high efficacy (98% reduction in parasitemia) when dosed orally at 4 × 50 mg/kg. Generally, the compounds were noncytotoxic to mammalian cells. |
en_ZA |
dc.description.department |
Biochemistry |
en_ZA |
dc.description.department |
Genetics |
en_ZA |
dc.description.department |
Microbiology and Plant Pathology |
en_ZA |
dc.description.department |
UP Centre for Sustainable Malaria Control (UP CSMC) |
en_ZA |
dc.description.embargo |
2022-04-12 |
|
dc.description.librarian |
hj2021 |
en_ZA |
dc.description.sponsorship |
The University of Cape Town, South African Medical Research Council and South African Research Chairs Initiative of the Department of Science and Innovation, administered through the South African National Research Foundation (NRF) and a NRF Community of Practice on ‘Evaluating Malaria Control Interventions’. |
en_ZA |
dc.description.uri |
http://pubs.acs.org/loi/jmcmar |
en_ZA |
dc.identifier.citation |
Dziwornu G.A., Coertzen D., Leshabane M. et al. 2021, 'Antimalarial benzimidazole derivatives incorporating phenolic Mannich base side chains inhibit microtubule and hemozoin formation : structure–activity relationship and in vivo oral efficacy studies', Journal of Medicinal Chemistry, vol. 64, no. 8, pp. 5198-5215. |
en_ZA |
dc.identifier.issn |
0022-2623 (print) |
|
dc.identifier.issn |
1520-4804 (online) |
|
dc.identifier.other |
10.1021/acs.jmedchem.1c00354 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/80929 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
American Chemical Society |
en_ZA |
dc.rights |
This document is the Accepted Manuscript version of a Published Work that appeared in final form in Journal of Medicinal Chemistry, © 2020 American Chemical Society after peer review and technical editing by the publisher. |
en_ZA |
dc.subject |
Antiplasmodium |
en_ZA |
dc.subject |
Antimalarials |
en_ZA |
dc.subject |
Gametocytes |
en_ZA |
dc.subject |
Benzimidazole |
en_ZA |
dc.subject |
Phenolic Mannich bases |
en_ZA |
dc.subject |
Hemozoin |
en_ZA |
dc.subject |
Microtubules |
en_ZA |
dc.title |
Antimalarial benzimidazole derivatives incorporating phenolic Mannich base side chains inhibit microtubule and hemozoin formation : structure–activity relationship and in vivo oral efficacy studies |
en_ZA |
dc.type |
Postprint Article |
en_ZA |